Evaluation of Pharmacokinetic and Safety of NVP-2102 and NVP-2102-R in Healthy Subjects

Phase 1CompletedNCT05023031

NVP Healthcare53 enrolled

Overview

The purpose of this study is to compare the pharmacokinetics and safety of NVP-2102 and NVP-2102-R.

Evaluate the pharmacokinetics and safety of NVP-2102 compared to NVP-2102-R

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Healthy Subjects

Interventions

NVP-2102DRUG

Tablet formulation for oral administration, single dose of NVP-2102 at Day 1

NVP-2102-RDRUG

Tablet formulation for oral administration, single dose of NVP-2102-R at Day 1

Eligibility

Sex: ALLMin age: 19 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy subject, 19 years of age or older * Subjects who signed informed consent * Body mass index(BMI) of 18 to 30.0 kg/㎡ Exclusion Criteria: * Subject who has clinically significant medical history * Inadequate subject for the clinical trial by the investigator's decision * Subjects participated in another clinical trial within 6 months prior to the first administration of investigational product

Locations (1)

H Plus Yangji Hospital

Seoul, Nambusunhwan-ro, South Korea